Kadcyla®▼(trastuzumab emtansine)

EU Healthcare Professional Information Feedback Form

Please provide us with feedback on the quality and utility of the materials within this Kadcyla Risk Management Educational Pack.

Once completed please return this questionnaire in the reply paid envelope provided.
If you prefer to complete these questions online please go to www.RocheRMPsurvey.co.uk

Please tell us the extent to which you agree / disagree with the following statements by marking the scale provided.

Q. These educational materials helped me differentiate between the medicines: Herceptin® (trastuzumab), Herceptin® subcutaneous (trastuzumab), and Kadcyla (trastuzumab emtansine)

1	2	3	4	5
strongly disagree	disagree	neither agree nor disagree	agree	strongly agree

Q. I understand the risks which may occur whilst prescribing any of Herceptin (trastuzumab), Herceptin subcutaneous (trastuzumab), or Kadcyla (trastuzumab emtansine)

1	2	3	4	5
strongly disagree	disagree	neither agree nor disagree	agree	strongly agree

Q. I understand the mitigation measures described which will help to prevent such medication errors

1	2	3	4	5
strongly disagree	disagree	neither agree nor disagree	agree	strongly agree

Q. These educational materials have, and will in the future, help to minimise risk in the prescription, preparation, or administration of Herceptin (trastuzumab), Herceptin subcutaneous (trastuzumab), and Kadcyla (trastuzumab emtansine)?

1	2	3	4	5
strongly disagree	disagree	neither agree nor disagree	agree	strongly agree

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.medicinesauthority.gov.mt/adrportal and sent by email to postlicensing.medicinesauthority@gov.mt or posted to ADR Reporting, The Medicines Authority Post-licensing Directorate, 203, Level 3, Rue D'Argens, Gżira GŻR 1368, MALTA. As Kadcyla is a biological medicine, healthcare professionals are encouraged to report adverse reactions by brand name and batch number. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

RXUKTDM100053e / January 2014

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan